SABCS is one of the world’s most influential scientific meetings dedicated to breast cancer research and treatment. Are you attending? Meet Parisa Valadan, Associate Director to discuss how our team can help you clarify your strategy and uncover opportunities to accelerate impact.

Imagine a simple blood test that could screen for dozens of cancers, long before symptoms appear. This is the promise of Multi-Cancer Early Detection (MCED), a rapidly emerging field that has the potential to transform how we approach cancer screening globally. As with any breakthrough, the success of MCED will depend not only on the science, but also on public awareness, understanding and interest, healthcare system readiness, and equitable access.

As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants. Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 3 are available for immediate purchase, with Wave 4 launching soon.

We are delighted to be attending the American Society of Clinical Oncology annual conference, May 30 - June 3 2025 in Chicago. Purdie Pascoe’s experts, Marianne Fillion and Vanessa Slade will be attending the conference, and are looking forward to meeting delegates at the biggest event in Oncology across the globe.

Purdie Pascoe is conducting an ongoing ctDNA Cancer Monitoring US Landscape syndicated study. The first two waves are available for purchase, with a third wave set to launch soon.

Purdie Pascoe is delighted to announce the findings from the second wave of our syndicated ctDNA Cancer Monitoring study have been published and are available to purchase. If you are interested in purchasing both waves, our consultants would be delighted to discuss a special pricing agreement. 

Are ctDNA monitoring tests being used in clinical practice? Which ctDNA monitoring tests are oncologists currently using, and why? What are their unmet needs and expectations from a new test? Purdie Pascoe is delighted to announce the findings from the first wave of our syndicated ctDNA Cancer Monitoring study have been published.

Tumor agnostic indications present specific challenges that must be addressed to achieve a successful launch and ensure wide access for all patients. To prepare for these complex product and indications launches, it is paramount for commercial teams to gain insights on tumor agnostic testing behaviors, including awareness, adoption, drivers and barriers.